Core Insights - On August 4, 2025, the top three companies by trading volume in the Southbound Stock Connect were Yingfu Fund (02800), Hang Seng China Enterprises (02828), and InnoCare Pharma (02577) with trading volumes of 94.85 billion, 46.53 billion, and 41.25 billion respectively [1] - In the Southbound Stock Connect for Shenzhen, the top three companies were Yingfu Fund (02800), Tencent Holdings (00700), and Hang Seng China Enterprises (02828) with trading volumes of 50.64 billion, 22.09 billion, and 17.90 billion respectively [1] Southbound Stock Connect (Shanghai) Active Companies - Yingfu Fund (02800) had a trading amount of 94.85 billion with a net buy of -94.77 billion [2] - Hang Seng China Enterprises (02828) recorded a trading amount of 46.53 billion with a net buy of -45.52 billion [2] - InnoCare Pharma (02577) achieved a trading amount of 41.25 billion with a net buy of +2.80 billion [2] - Tencent Holdings (00700) had a trading amount of 24.71 billion with a net buy of +6.17 billion [2] - Alibaba-W (09988) recorded a trading amount of 20.88 billion with a net buy of +7.26 billion [2] Southbound Stock Connect (Shenzhen) Active Companies - Yingfu Fund (02800) had a trading amount of 50.64 billion with a net buy of -50.58 billion [2] - Tencent Holdings (00700) recorded a trading amount of 22.09 billion with a net buy of -5.65 billion [2] - Hang Seng China Enterprises (02828) achieved a trading amount of 17.90 billion with a net buy of -17.74 billion [2] - Alibaba-W (09988) had a trading amount of 12.93 billion with a net buy of +228.97 million [2] - InnoCare Pharma (02577) recorded a trading amount of 12.76 billion with a net buy of +823.66 million [2]

Market Overview - On August 4, the Hang Seng Index rose by 0.92%, closing at 24,733.45 points, while southbound funds through the Stock Connect recorded a net sell of 18.092 billion HKD [1] - The total trading volume for the Stock Connect on August 4 was 130.07 billion HKD, with a net sell of 18.092 billion HKD [1] Trading Activity - In the Shanghai Stock Connect, the trading volume was 83.126 billion HKD with a net sell of 11.124 billion HKD, while in the Shenzhen Stock Connect, the trading volume was 46.944 billion HKD with a net sell of 6.968 billion HKD [1] - The most actively traded stock in the Shanghai Stock Connect was the Tracker Fund of Hong Kong (盈富基金), with a trading volume of 9.485 billion HKD, followed by Hang Seng China Enterprises and InnoCare Pharma, with trading volumes of 4.653 billion HKD and 4.125 billion HKD respectively [1] Net Buy/Sell Analysis - Alibaba-W recorded the highest net buy amount of 726 million HKD, despite a closing price drop of 0.60% [1] - The Tracker Fund of Hong Kong had the highest net sell amount of 9.477 billion HKD, while its closing price increased by 0.88% [1] - In the Shenzhen Stock Connect, the Tracker Fund of Hong Kong also led in trading volume with 5.064 billion HKD, and had a net sell of 5.058 billion HKD, closing up by 0.88% [2] Key Stocks Performance - Kuaishou-W had the highest net buy amount in the Shenzhen Stock Connect, with a net buy of 220 million HKD and a closing price increase of 3.22% [2] - Tencent Holdings and Hang Seng China Enterprises followed in trading volume with 2.709 billion HKD and 1.790 billion HKD respectively [2]

8月4日恒生指数上涨0.92%，南向资金全天合计成交金额为1300.70亿港元，其中，买入成交559.89亿港 元，卖出成交740.81亿港元，合计净卖出金额180.92亿港元。具体来看，港股通（深）累计成交金额 469.44亿港元，买入成交199.88亿港元，卖出成交269.56亿港元，合计净卖出金额69.68亿港元；港股通 （沪）累计成交金额831.26亿港元，买入成交360.01亿港元，卖出成交471.25亿港元，合计净卖出金额 111.24亿港元。 成交活跃股方面，今日上榜个股中，南向资金成交金额最多的是盈富基金，合计成交额145.49亿港元， 恒生中国企业、英诺赛科成交额紧随其后，分别成交64.42亿港元、54.01亿港元。以净买卖金额统计， 净买入的个股共有7只，阿里巴巴-W净买入额为7.28亿港元，净买入金额居首，该股收盘股价下跌 0.60%，英诺赛科净买入额为3.63亿港元，快手-W净买入额为2.20亿港元。净卖出金额最多的是盈富基 金，净卖出145.35亿港元，该股收盘股价上涨0.88%，恒生中国企业、南方恒生科技遭净卖出63.26亿港 元、14.53亿港元。 今日上榜个股中，阿里巴巴-W、 ...

8月4日消息，南向资金今日成交1300.70亿港元，净流出约180.92亿港元。其中沪港股通净流出约111.24 亿港元，深港股通净流出约69.68亿港元 交易所数据显示，8月4日南向资金动向： 大幅净买入：阿里巴巴-W(09988.HK)7.28亿港元、英诺赛科(02577.HK)3.63亿港元、快手- W(01024.HK)2.20亿港元、中芯国际(00981.HK)2.18亿港元、腾讯控股(00700.HK)5260.40万港元、理想 汽车-W(02015.HK)4081.28万港元。 大幅净卖出：盈富基金(02800.HK)1453488.10万港元、恒生中国企业(02828.HK)632565.26万港元、南方 恒生科技(03033.HK)145309.15万港元、康方生物(09926.HK)32314.28万港元。 恒生中国企业今日涨1.00%，沪港股通净卖出455163.71万港元，深港股通净卖出177401.55万港元。 南方恒生科技今日涨1.32%，沪港股通净卖出145309.15万港元。 康方生物今日跌2.69%，深港股通净卖出32314.28万港元。 成交详情 阿里巴巴W今日跌0.60% ...

Core Viewpoint - The article discusses the emergence of bispecific antibodies targeting both PD-(L)1 and VEGF in cancer treatment, highlighting the approval of Ivoris monoclonal antibody as the first of its kind in China, which has sparked a wave of interest and competition in this field [2][3]. Group 1: Overview of Bispecific Antibodies - The combination of immune therapy and anti-angiogenesis drugs has shown significant clinical success, but traditional dual-drug regimens face challenges such as dosage control and side effects [2]. - Ivoris monoclonal antibody, developed by Kangfang Biopharma, is the first PD-1/VEGF bispecific antibody approved globally, marking a significant milestone in the industry [2][3]. Group 2: Competitive Landscape - Over 17 PD-(L)1/VEGF bispecific antibodies are currently in clinical trials globally, indicating a highly competitive environment with numerous companies entering the market [3]. - The competition is characterized by a diverse range of technical approaches and designs, leading to a "hundred flowers bloom" scenario in the industry [3][4]. Group 3: Key Technical Variables - Three critical variables differentiate the designs of PD-(L)1/VEGF bispecific antibodies: 1. Selection of immune targets (PD-1 vs. PD-L1), which affects the breadth of immune response and potential side effects [6]. 2. Choice of anti-angiogenesis targets (VEGF vs. VEGFR), influencing the mechanism of action and potential adverse effects [6]. 3. Antibody structure and fusion methods, which impact the drug's pharmacological properties and production processes [9]. Group 4: Representative Technical Designs - Kangfang Biopharma's Ivoris features a symmetrical tetravalent structure ("2+2 design") that enhances affinity for both PD-1 and VEGF targets, showcasing a promising design in the bispecific antibody landscape [13]. - Other companies are exploring different fusion strategies, such as C-terminal and N-terminal fusions with nanobodies, which may offer advantages in tissue penetration and efficacy [14]. Group 5: Clinical Relevance - The article emphasizes that despite theoretical advantages of various designs, the true measure of success will be clinical efficacy and safety data, as past experiences with PD-1 and PD-L1 antibodies have shown that theoretical differences do not always translate into clinical outcomes [16][17]. - The focus should remain on actual clinical results, production efficiency, and market competitiveness rather than solely on innovative structural designs [20].

Group 1 - The stock prices of several biotech companies have experienced declines, with 康方生物 (09926.HK) down 5.37%, 泰格医药 (03347.HK) down 3.34%, 药明康德 (02359.HK) down 3.15%, and 君实生物 (01877.HK) down 2.64% [1]

"创新药已从'主题投资'转向'产业趋势投资'。"某公募基金医药行业研究员表示，政策端，医保谈判简化、审评审 批加速等改革持续落地；技术端，ADC（抗体偶联药物）、双抗、细胞治疗等前沿领域进入成果收获期；资本 端，美联储加息周期接近尾声，全球生物医药投融资环境回暖，共同构成了本轮行情的底层逻辑。 从"至暗时刻"到"聚光灯下"，医药行业的反转行情印证了"创新驱动增长"的长期逻辑。（水手） 医药基金"王者归来"，单月最高涨34%。板块的强劲表现直接反映在基金净值上。Wind数据显示，截至7月31日， 全市场200余只医药主题基金（AC份额合并计算）中，超过80%年内实现正收益。其中，永赢医药健康A以34.2% 的单月涨幅领跑，华富健康文娱A、中银创新医疗A等7只基金涨幅超30%，形成明显的"赚钱效应"。 拉长时间维度看，医药基金的复苏势头更为显著。年内业绩排名前十的主动权益类基金中，中银创新医疗A、融 通健康产业A等9只产品均聚焦医药领域，与去年同期的"无人问津"形成鲜明对比。某头部基金公司市场部负责人 透露："近期渠道调研显示，投资者对医药基金的关注度提升至2021年以来的最高水平，新发基金中医疗健康主题 占比超 ...

Core Viewpoint - The article highlights the performance of various sectors in the stock market, particularly focusing on the top-performing stocks in July and the anticipated trends for August, with a strong emphasis on the electronic, basic chemical, pharmaceutical, and mechanical equipment industries [1][4][9]. Summary by Sections July Performance - In July, the innovative drug sector showed remarkable performance, with Kangchen Pharmaceutical leading with a 107% monthly increase, followed by Borui Pharmaceutical at 82%, and Kangfang Biotech at 68% [2][3]. - The electronic and communication sectors also had notable performers, such as Dongshan Precision with a 55% increase and Tonglian Precision with a 50% increase [3]. - Over 30 brokerage firms reported a monthly return of over 5% from their recommended stocks, with six firms exceeding 10% [3]. August Outlook - As of August, the latest stock recommendations show a strong focus on electronic, basic chemical, pharmaceutical, and mechanical equipment sectors [4][9]. - Dongfang Caifu is highlighted as the most popular stock, recommended by six institutions, with expectations of significant price increases in the securities sector [4][9]. - Luoyang Molybdenum is also recommended, with projections of continued growth in copper production and high copper prices leading to increased revenue and profit [5]. Market Predictions - Analysts predict that the market may reach new highs in the second half of the year, driven by sustained capital inflows and opportunities in emerging industries [9][10]. - The focus for investment strategies includes sectors benefiting from "anti-involution" policies, such as coal, steel, and photovoltaic industries, as well as technology growth areas like AI and innovative pharmaceuticals [9][10].

从中证沪港深500医药卫生指数持仓的市场板块来看，香港证券交易所占比37.87%、上海证券交易所占 比33.61%、深圳证券交易所占比28.52%。 从中证沪港深500医药卫生指数持仓样本的行业来看，化学药占比36.20%、制药与生物科技服务占比 18.33%、生物药品占比18.14%、医疗器械占比11.07%、中药占比8.56%、医疗商业与服务占比7.70%。 资料显示，该指数系列样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五 的下一交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一 个定期调整日前，权重因子一般固定不变。特殊情况下将对该指数系列样本进行临时调整。当样本退市 时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处 理。当中证沪港深500指数、中证沪港深互联互通中小综合指数和中证沪港深互联互通综合指数样本发 生变动时，将进行相应调整。 金融界8月1日消息，上证指数下跌0.37%，中证沪港深500医药卫生指数 (沪港深500医药，H30463)下跌 1.74%，报8507.96点，成交额405.94亿元 ...

瑞银指，该药物自今年1月纳入国家医保目录后销售快速增长，5月获批NSCLC一线治疗新适应症，有 望通过2025年医保谈判进一步贡献增量收入，将AK112在中国及全球销售高峰值上调至12亿及146亿美 元。 瑞银发布研报称，康方生物(09926)核心产品AK112(ivonescimab)在非小细胞肺癌(NSCLC)外的适应症展 现巨大潜力，除NSCLC的6项适应症外，公司另启动6项三期临床试验，覆盖胆管癌、三阴性乳腺癌、 胰腺癌等一线治疗领域，适应症广度居同类药物之首，重申"买入"评级，并将目标价从112.1港元大幅 上调至197.5港元。 ...